RT Journal Article
SR Electronic
T1 EBV deletions as biomarkers of response to treatment of Chronic Active Epstein Barr Virus
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.18.20248315
DO 10.1101/2020.12.18.20248315
A1 Venturini, Cristina
A1 Houldcroft, Charlotte J
A1 Lazareva, Arina
A1 Wegner, Fanny
A1 Morfopoulou, Sofia
A1 Amrolia, Persis J.
A1 Golwala, Zainab
A1 Rao, Anupama
A1 Marks, Stephen D.
A1 Simmonds, Jacob
A1 Yoshikawa, Tetsushi
A1 Farrell, Paul J.
A1 Cohen, Jeffrey I.
A1 Worth, Austen J.
A1 Breuer, Judith
YR 2021
UL http://medrxiv.org/content/early/2021/02/18/2020.12.18.20248315.abstract
AB Chronic active Epstein Barr Virus (CAEBV) is a rare condition occurring in previously healthy individuals associated with persistent EBV viraemia, fever, lymphadenopathy and hepatosplenomegaly. Viral deletions have been found in CAEBV and other lymphomas. However, it is unclear how stable these deletions are, whether they are present in different sites and how they evolve overtime. We sequenced fourteen longitudinal blood samples from three European CAEBV patients and compared with CAEBV saliva samples and other sequences from EBV-related conditions. We observed large EBV deletions in blood, but not saliva from CAEBV patients. Deletions were stable over time but were lost following successful treatment. Our results are consistent with the likelihood that certain deletions in the virus from CAEBV patients are associated with the evolution and persistence of haematological clones. We propose that the loss of deletions following successful treatment should be investigated as a potential biomarker to aid CAEBV management.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCV was supported by the Wellcome Trust Collaborative Award [204870/Z/16/Z]; SM by a WT Henry Wellcome fellowship [206478/Z/17/Z]. PJF was supported by MRC grant MR/S022597/1 and by NIHR Imperial BRC. JB is supported by the NIHR UCL/UCLH BRC. This work was supported by the intramural research program of the National of Allergy and Infectious Diseases.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All samples were supplied to the study in an anonymized form. Approval for use of anonymized residual diagnostic specimens was obtained through the University College London/University College London Hospitals (UCL/UCLH) Pathogen Biobank National Research Ethics Service Committee London Fulham (Research Ethics Committee reference: 12/LO/1089). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequence reads for CAEBV and PID patients have been deposited in NCBI Sequence Read Archive under BioProject ID PRJEB41945. All accession numbers for the rest of the dataset are available in Table S1.EBVEpstein-Barr VirusCAEBVChronic active Epstein Barr VirusPBSCTperipheral blood stem cell transplantHLHHemophagocytic LymphohistiocytosisIMInfectious MononucleosisPTLDPost Transfusion Lymphoproliferative DiseaseHLHodgkin’s lymphomaPIDPrimary Immunodeficiency.